BioCryst Pharmaceuticals (NASDAQ: BCRX) insider transactions

In the twelve months to 10 November 2026, executives and directors of BioCryst Pharmaceuticals reported 10 open-market sales of 487,876 shares ($4.1m) and 0 open-market purchases, by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in BioCryst Pharmaceuticals shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
31 August 2026	Frank Steven	Director	Grant or award	+1,288	$9.70	36,747	Form 4
31 August 2026	McKee Amy E	Director	Grant or award	+644	$9.70	47,821	Form 4
31 August 2026	Milano Vincent	Director	Grant or award	+1,159	$9.70	109,642	Form 4
31 August 2026	Milne Jill C.	Director	Grant or award	+1,288	$9.70	33,226	Form 4
31 August 2026	Stonehouse Jon P	Director	Grant or award	+644	$9.70	1,340,419	Form 4
11 June 2026	Heggie Theresa	Director	Grant or award	+15,294	—	80,646	Form 4
11 June 2026	McKee Amy E	Director	Grant or award	+15,294	—	47,177	Form 4
11 June 2026	Stonehouse Jon P	Director	Grant or award	+15,294	—	1,339,775	Form 4
11 June 2026	Milano Vincent	Director	Grant or award	+15,294	—	108,483	Form 4
11 June 2026	Sanders Machelle	Director	Grant or award	+15,294	—	45,936	Form 4
11 June 2026	Frank Steven	Director	Grant or award	+15,294	—	35,459	Form 4
11 June 2026	Levin Alan G	Director	Grant or award	+15,294	—	79,565	Form 4
11 June 2026	Galson Steven K	Director	Grant or award	+15,294	—	27,794	Form 4
11 June 2026	Milne Jill C.	Director	Grant or award	+15,294	—	31,938	Form 4
29 May 2026	Frank Steven	Director	Grant or award	+1,262	$8.91	20,165	Form 4
29 May 2026	Milano Vincent	Director	Grant or award	+1,122	$8.91	93,189	Form 4
29 May 2026	McKee Amy E	Director	Grant or award	+631	$8.91	31,883	Form 4
29 May 2026	Stonehouse Jon P	Director	Grant or award	+631	$8.91	1,324,481	Form 4
29 May 2026	Milne Jill C.	Director	Grant or award	+1,262	$8.91	16,644	Form 4
18 May 2026	McKee Amy E	Director	Open-market sale	−11,180	$8.97	31,252	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the BioCryst Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.